The conference highlighted a strong focus on executing the pivotal cema-cel trial in lymphoma, with interim data showing high MRD clearance and excellent safety. Rapid MRD adoption and community access drive a multi-billion dollar market opportunity, while the autoimmune pipeline advances with innovative dual-targeting CARs and robust financial runway.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.